Concepedia

David Stirling

DS

Statistics

Publications

80

Citations

11.5K

H-Index

46

Active since

1977

Affiliations

Bristol-Myers Squibb (Switzerland)(Current)

St George's, University of London

St George's Hospital

University of Warwick

University of the West of Scotland

David Stirling is an author at Bristol-Myers Squibb (Switzerland) specializing in pharmacology, medicine, and thalidomide analogs.

Publications per year

1977–2020

80

Publications

80

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima et al. · Blood · 2001 · 905 citations

Medicine, Immunology, Oncology +12

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Teru Hideshima, Dharminder Chauhan, Yoshihito Shima et al. · Blood · 2000 · 859 citations

Medicine, Oncology, Pharmacology +16

Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin

Sarah D. Brown, Paola Nativo, J.L. Smith et al. · Journal of the American Chemical Society · 2010 · 855 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Laura G. Corral, Patrick Haslett, George W. Muller et al. · PubMed · 1999 · 731 citations

Medicine, Immunology, Pharmacology +17

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

Laura G. Corral, Patrick Haslett, George W. Muller et al. · The Journal of Immunology · 1999 · 654 citations · Full text

Medicine, Immunology, Pharmacology +16

1–5 of 80